Synergy for Building the Future of Iran's Pharmaceutical Industry: Rahnab Pharmed: An integrated value chain spanning plasma procurement, R&D, novel drug manufacturing, vaccines, biologics, and cellular therapies.
National Biopharma
Industrial Infrastructure
Rahnab Pharmed is a specialized healthcare and pharmaceutical holding that, relying on an ecosystem of specialized knowledge-based enterprises, has forged an end-to-end integrated value chain spanning raw material and plasma supply, R&D, advanced pharmaceuticals, biologics, vaccines, novel therapeutic formulations, and cell therapy. Our strategy is founded upon creating synergy across group companies, advancing cutting-edge biotechnology, localizing strategic healthcare products, and meeting the critical needs of the national healthcare system.
Integrating full supply chain processes, from plasma collection to advanced cell therapy and strategic vaccine development at the highest international standards.
Plasma Collection & Fractionation
Human plasma collection through a network of eight apheresis centers and production of vital plasma-derived medicines including Albumin, IVIG, Fibrinogen, and Factor VIII.
Insulin & Critical Therapeutics
Developing manufacturing capacity for eight types of insulin required by the country to reduce import dependency and secure medication for diabetic patients.
Recombinant Vaccines & Prevention
Manufacturing Papilloguard and Pneumoguard vaccines and developing Zonaguard to prevent diseases and strengthen national immunization infrastructure.
Cell Therapy & CAR-T Platforms
Developing and manufacturing CAR-T cells and localizing advanced cellular therapies; advancing toward treating intractable diseases with next-generation technologies.
Hyperimmune Sera & Antivenoms
Producing approximately 70% of Iran's scorpion and snake antivenom requirements and providing emergency therapeutic sera for venomous envenomation.
Biotech Acceleration & Venture Incubation
Identifying scientific potential and translating it into scalable products; acting as the essential bridge connecting knowledge, technology, and the modern biopharma industry.
Synergistic alignment of leading knowledge-based companies across bioprocesses, plasma fractionation, vaccines, and cell therapies under unified strategic governance.
Nozhin Zist Pharmed
Development and manufacturing of plasma-derived therapeutics and advanced biologics — producing Albumin, IVIG, Fibrinogen, and Factor VIII.
Tamin Plasma Nozhin
First node in the plasma therapeutics supply chain — collecting and procuring human plasma across eight active centers nationwide.
Baya Zist Pharmed
A decisive step toward national insulin self-sufficiency — developing production capacity for eight types of insulin and novel therapeutics.
Padra Serum Alborz
Producing over 70% of Iran's demand for scorpion and snake antivenoms — with an active focus on regional export expansion.
Persis Gene Par
Leading accelerator and biotechnology hub — developing pharmaceutical molecules and strengthening the bridge between academia and industry.
KarayaKhteh Tejhiz Azma
Pioneering cell therapy in Iran — developing and manufacturing CAR-T cells and localizing advanced cellular therapies for diverse pathologies.
Nivad Pharmed Salamat
Development and manufacturing of Papilloguard, Pneumoguard, and Zonaguard vaccines — fortifying national immunization infrastructure.
This strategic milestone concludes national reliance on sending plasma abroad for fractionation, anchoring the production of critical plasma-derived therapeutics within domestic borders.
Official entry into the elite club of advanced cancer cellular therapy manufacturers in West Asia.
Nationwide coverage of emergency treatment centers for venomous bites, saving thousands of lives in frontier regions.